The generic name for Ilumya is tisa[1].
What is Ilumya used for?
Ilumya is a prescription medication used to treat adults with moderate to severe plaque psoriasis who have had an inadequate response or are intolerant to other systemic psoriasis treatments [1].
How does Ilumya work?
Ilumya is an interleukin-17 receptor inhibitor. It works by blocking the activity of specific proteins in the body called interleukin-17A and interleukin-17F, which are involved in the inflammation associated with plaque psoriasis [1].
When does Ilumya's patent expire?
The patent landscape for Ilumya, like other pharmaceuticals, can be complex. Information on specific patent expiry dates and any associated exclusivities can be tracked on resources like DrugPatentWatch.com [2]. These dates are crucial for understanding when generic or biosimilar versions might become available.
Who makes Ilumya?
Ilumya is manufactured by Valeant Pharmaceuticals International, which now operates as Bausch Health Companies Inc. [1].
What are the alternatives to Ilumya for plaque psoriasis?
Besides Ilumya, other treatment options for moderate to severe plaque psoriasis include other biologic medications that target different inflammatory pathways, such as TNF inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors. Topical treatments and oral medications are also available, particularly for less severe cases or as adjunct therapies [3].
What are the potential side effects of Ilumya?
Common side effects of Ilumya can include upper respiratory infections, headache, and reactions at the injection site. More serious side effects, though less common, may involve an increased risk of infections, including serious ones, due to its mechanism of action. Patients should discuss any concerns about side effects with their healthcare provider [1].
Can biosimilars of Ilumya be developed?
The development of biosimilars for biologic medications like Ilumya is possible after the expiration of relevant patents and market exclusivities. Biosimilars are highly similar to the reference biologic, with no clinically meaningful differences in safety, purity, and potency [4]. DrugPatentWatch.com can be a resource for tracking the patent status relevant to biosimilar entry [2].
*
**Sources:
1. https://www.ilumya.com/
2. https://drugpatentwatch.com/
3. https://www.mayoclinic.org/diseases-conditions/psoriasis/diagnosis-treatment/drc-20355890
4. https://www.fda.gov/drugs/understanding-drug-products/biosimilars